Page last updated: 2024-11-05

2-phenylbenzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PBT2 compound: a metal-protein-attenuating compound that may be useful in treating Alzheimer's disesae [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-phenylbenzothiazole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10016012
CHEMBL ID3634131
SCHEMBL ID8342589
MeSH IDM0192740
PubMed CID13439
CHEMBL ID2272273
SCHEMBL ID94005
MeSH IDM0192740

Synonyms (91)

Synonym
5,7-dichloro-2-(dimethylaminomethyl)quinolin-8-ol
1123760-88-2
pbt2
pbt 2
pbt 2 (anti-alzheimer agent)
pbt2 compound
pbt-2
SCHEMBL8342589
CHEMBL3634131
pbt-1033
747408-78-2
8-quinolinol, 5,7-dichloro-2-((dimethylamino)methyl)-
pb 1033
unii-q7k6gjq4o4
q7k6gjq4o4 ,
gtpl11108
pbt1033
P17129
AS-53797
5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol
pbt-2; pbt1033; pbt2; pbt 1033; pbt 2
BCP19805
5,7-dichloro-2-((dimethylamino)methyl)quinolin-8-ol
mfcd30749371
DB05565
Q7118446
EN300-305718
EX-A4581
AKOS037644486
HY-105321
DTXSID701029571
5,7-dichloro-2-[(dimethylamino)methyl]-8-quinolinol
pbt 1033
CS-0025730
Z2525155501
4-27-00-01385 (beilstein handbook reference)
unii-fo573g4bgt
fo573g4bgt ,
nsc-1854
2-phenylbenzothiazole
wln: t56 bn dsj cr
nsc2034
benzothiazole, 2-phenyl-
nsc1854
883-93-2
nsc-2034
IFLAB1_004405
ai3-00636
einecs 212-935-3
nsc 1854
brn 0141340
nsc 2034
2-phenyl-1,3-benzothiazole
IDI1_010160
STK360257
2-phenylbenzothiazole, 97%
inchi=1/c13h9ns/c1-2-6-10(7-3-1)13-14-11-8-4-5-9-12(11)15-13/h1-9
AKOS000454336
AKOS000470728
HMS1424I05
P1130
A842568
CCG-103648
FT-0613325
2-phenylbenzthiazole
2-phenylbenzo[d]thiazole
CHEMBL2272273
2-phenyl benzothiazole
SCHEMBL94005
AB00627448-04
W-100406
2-phenyl-1,3-benzothiazole #
AC-29863
mfcd00005777
DTXSID80236946
SR-01000395348-1
sr-01000395348
Z50128948
benzothiazole,phenyl-
100182-84-1
SY032902
NCGC00335906-01
10.14272/XBHOUXSGHYZCNH-UHFFFAOYSA-N.1
doi:10.14272/xbhouxsghyzcnh-uhfffaoysa-n.1
2-phenylbenzothiazol
AC1645
CS-11906
Q27278099
nsc-817068
nsc817068
CS-0095852

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"PBT2 is a metal-protein attenuating compound (MPAC) that affects the Cu2(+)-mediated and Zn2(+)-mediated toxic oligomerisation of Abeta seen in Alzheimer's disease (AD)."( Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Ames, D; Batsman, S; Blennow, K; Bush, AI; Harrison, J; Lannfelt, L; Masters, CL; Murdoch, R; Ritchie, CW; Targum, S; Wilson, J; Zetterberg, H, 2008
)
0.35
" 42 (54%) patients had at least one treatment emergent adverse event (10 [50%] on PBT2 50 mg, 18 [62%] on PBT2 250 mg, and 14 [48%] on placebo)."( Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Ames, D; Batsman, S; Blennow, K; Bush, AI; Harrison, J; Lannfelt, L; Masters, CL; Murdoch, R; Ritchie, CW; Targum, S; Wilson, J; Zetterberg, H, 2008
)
0.35
" elegans model of full length Aß₁₋₄₂ expression can now be adopted for use in screens to rapidly identify and assist in development of potential therapeutics and to study underlying toxic mechanism(s) of Aß."( Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.
Barnham, KJ; Bush, AI; Cherny, RA; Kenche, VB; Link, CD; Masters, CL; McColl, G; Pukala, TL; Roberts, BR; Roberts, CM; Ryan, TM, 2012
)
0.38
" Six serious adverse events (acute coronary syndrome, major depression, pneumonia, suicide attempt, viral infection, and worsening of Huntington's disease) occurred in five participants in the PBT2 250 mg group, three (fall with subdural haematoma, suicide attempt, and hospital admission for stabilisation of Huntington's disease) occurred in two participants in the PBT2 100 mg group, and one (increasing aggression) occurred in a participant in the placebo group."( Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
, 2015
)
0.42
"PBT2 was generally safe and well tolerated in patients with Huntington's disease."( Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1824262Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1255354Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Cu uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control2015ACS medicinal chemistry letters, Sep-10, Volume: 6, Issue:9
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
AID1824260Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1255357Reversal of Zn-induced human soluble amyloid beta (1 to 42) aggregation after 30 mins by bis-ANS-based fluorometric analysis2015ACS medicinal chemistry letters, Sep-10, Volume: 6, Issue:9
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
AID1255355Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Zn uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control2015ACS medicinal chemistry letters, Sep-10, Volume: 6, Issue:9
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
AID1824261Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1265778Antibacterial activity against Bacillus subtilis assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID1265774Cytotoxicity against human MCF7 cells assessed as cell death after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID1265779Antibacterial activity against Salmonella assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID1741933Antiproliferative activity against human HeLa cells assessed as growth inhibition at 20 uM viability after 72 hrs by SRB assay relative to control2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of 2-(2-aminobenzo[d]thiazol-6-yl) benzo[d]oxazol-5-amine derivatives that regulated HPV relevant cellular pathway and prevented cervical cancer from abnormal proliferation.
AID1265775Cytotoxicity against human HeLa cells assessed as cell death after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID1265777Antibacterial activity against Escherichia coli assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID1265780Stability of the compound in GSH at 10'-5 M after 48 hrs by UV-vis spectroscopic analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID1265776Antibacterial activity against Staphylococcus aureus assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.82)18.7374
1990's1 (1.82)18.2507
2000's4 (7.27)29.6817
2010's38 (69.09)24.3611
2020's11 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.75 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (9.68%)5.53%
Trials0 (0.00%)5.53%
Reviews6 (19.35%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other22 (70.97%)84.16%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]